Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DarioHealth Corp.DRIO · Entity 7024 | Director · Chief Executive Officer | August 12, 2024 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DarioHealth Corp.
Report date August 12, 2024 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,432 |
Reported balance
After 2024-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-12 · Conversion · Acquired 579 · Balance 157,432 F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. |
| Common StockSEC Table I · non-derivative | Direct | 454,432 |
Reported balance
After 2026-09-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-24 · Grant · Acquired 297,000 · Balance 454,432 F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2024-08-04 | Direct | 0 |
Reported balance
After 2024-08-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-12 · Conversion · Disposed 30 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Dicilyon Consulting and Investment Ltd. | 1,894 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,894 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
F2: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion.
F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 297,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-111343 · tm2626098-1_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454,432 F3 · date: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 16:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-090006 · tm2526001-7_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,853 F1 · date: The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period. F2 · balance_after: The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 18:12 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 5,000 | $0.88 | $4,400.00 |
DisclosureSEC source: 0001104659-24-094109 · tm2422950-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,937,059 Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 5,000 | $0.95 | $4,750.00 |
DisclosureSEC source: 0001104659-24-092417 · tm2422584-1_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,932,059 Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 5,000 | $0.93 | $4,650.00 |
DisclosureSEC source: 0001104659-24-092417 · tm2422584-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,927,059 Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 16:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 5,000 | $0.90 | $4,500.00 |
DisclosureSEC source: 0001104659-24-091264 · tm2422157-1_4seq1.xml · nonDerivative · entry 3 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,922,059 Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 16:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 3,000 | $0.90 | $2,700.00 |
DisclosureSEC source: 0001104659-24-091264 · tm2422157-1_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,917,059 Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 16:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,000 | $0.89 | $1,780.00 |
DisclosureSEC source: 0001104659-24-091264 · tm2422157-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,914,059 Read SEC document |
| August 12, 2024 Filed Sep 28, 2026 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionSeries B-2 Preferred Stock · Derivative | 30 | $1,000.00 Strike: $1,000.00 | $30,000.00 |
DisclosureSEC source: 0001104659-26-111343 · tm2626098-1_4seq1.xml · derivative · entry 4 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 579 shares Expires 2024-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Sep 28, 2026 20:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | ConversionCommon Stock | 579 | $19.10 | $11,058.90 |
DisclosureSEC source: 0001104659-26-111343 · tm2626098-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2 · shares: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. F2 · price: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. F2 · balance_after: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 16:19 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-032409 · tm248350-4_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,912,059 F1 · date: The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period. Read SEC document |
| May 04, 2023 Filed May 8, 2023 16:11 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseSeries B-2 Preferred Stock · Derivative | 30 | $1,000.00 Strike: $3.37 | $30,000.00 |
DisclosureSEC source: 0001104659-23-057156 · tm2315002-1_4seq1.xml · derivative · entry 3 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30 Underlying: Common Stock · Not disclosed shares Expires 2026-05-04 F2 · derivative.expiration_date: The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F3 · derivative.underlying_shares: The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 17:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 1,200 | $6.21 | $7,449.00 |
DisclosureSEC source: 0001104659-23-004642 · tm233645-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,059 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.23, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| May 18, 2022 Filed May 20, 2022 17:02 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 275,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-063450 · tm2216123-5_4seq.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,259 F1 · shares: The shares vest over three years as follows: 8.333% shall vest after 3 months from the grant date, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 20:51 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 800 | $19.08 | $15,263.04 |
DisclosureSEC source: 0001104659-21-136496 · tm2132400d1_4.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838,259 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.19, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 20:51 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 200 | $19.05 | $3,810.00 |
DisclosureSEC source: 0001104659-21-136496 · tm2132400d1_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,059 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.09, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 19:00 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 7,857 | $18.49 | $145,281.43 |
DisclosureSEC source: 0001104659-21-135188 · tm2132090-1_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,259 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.02 to $19.10, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 19:00 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 30,483 | $18.96 | $578,104.00 |
DisclosureSEC source: 0001104659-21-135188 · tm2132090-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,116 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.38, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 19:00 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 41,279 | $18.66 | $770,464.28 |
DisclosureSEC source: 0001104659-21-133842 · tm2131828-1_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,599 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.52 to $19.16, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 19:00 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 25,804 | $18.01 | $464,724.88 |
DisclosureSEC source: 0001104659-21-133842 · tm2131828-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,878 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.35, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| October 10, 2021 Filed Oct 12, 2021 16:46 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-125373 · tm2129692d2_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944,682 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2021. Read SEC document |
| July 18, 2021 Filed Jul 20, 2021 16:31 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-093983 · tm2122591-2_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,987 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2021. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 17:51 UTC | DarioHealth Corp. DRIO · Entity 7024 | SaleCommon Stock | 1,300 | $17.63 | $22,913.15 |
DisclosureSEC source: 0001104659-21-093563 · tm2122533-1_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,299 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.78, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 673 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061708 · tm2115112d2_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 944,599 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second quarter of 2021. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantRestricted Stock Grant | 413,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-006294 · tm213677-6_4seq1.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,926 F2 · date: The shares vest over three years as follows: 8.333% shall vest on March 31, 2021, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 2,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-006294 · tm213677-6_4seq1.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,768 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the first quarter of 2021. Read SEC document |
| January 19, 2021 Filed May 20, 2021 16:10 UTC Amendment | DarioHealth Corp. DRIO · Entity 7024 | GrantRestricted Stock Grant | 413,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-069894 · tm2117107d1_4a.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,926 F2 · date: The shares vest over three years as follows: 8.333% shall vest on March 31, 2021, and the remaining shares vest in 11 equal instalments every 3 months thereafter. Read SEC document |
| January 19, 2021 Filed May 20, 2021 16:10 UTC Amendment | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 2,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-069894 · tm2117107d1_4a.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,768 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the first quarter of 2021. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 16:09 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 7,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-116435 · tm2033754d4_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,500 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2020, and for additional compensation waived between April 2020 and July 2020 Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 16:10 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 15,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-085626 · tm2025176d5_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,313 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2020. Read SEC document |
| June 09, 2020 Filed Jun 9, 2020 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 500 | $6.06 | $3,030.00 |
DisclosureSEC source: 0001104659-20-071369 · tm2022156d1_4.xml · nonDerivative · entry 2 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,720 Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 500 | $5.98 | $2,990.00 |
DisclosureSEC source: 0001104659-20-071369 · tm2022156d1_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,220 Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 15,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044154 · tm2015091d4_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,720 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second quarter of 2020. Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 17:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 1,000 | $6.38 | $6,380.00 |
DisclosureSEC source: 0001104659-20-038347 · tm2013824-1_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,574 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:15 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 351,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021767 · tm207834-1_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,574 Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 16:07 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 15,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-008689 · tm206156d8_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,028 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the first quarter of 2020. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 15,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-076115 · tm1927375-2_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,426 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2019 in the aggregate amount of $66,610.47. Read SEC document |
| August 28, 2019 Filed Aug 28, 2019 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 10,000 | $0.35 | $3,490.00 |
DisclosureSEC source: 0001144204-19-042086 · tv528532_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119,398 F1 · shares: The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| July 09, 2019 Filed Jul 10, 2019 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 214,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-034297 · tv524960_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109,398 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second and third quarters of 2019 in the aggregate amount of $128,972. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 17:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 497,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-022458 · tv520227_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894,446 F1 · shares: Of the amount shown, 89,429 shares were awarded in lieu of a cash bonus compensation for the fiscal year of 2018 in the amount of $89,429.75. Read SEC document |
| January 27, 2019 Filed Jan 29, 2019 16:03 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 61,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-003515 · tv511869_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,397,436 F1 · shares: The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2019 in the amount of $61,969.43. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 16:01 UTC | DarioHealth Corp. DRIO · Entity 7024 | PurchaseCommon Stock | 4,000 | $0.84 | $3,360.00 |
DisclosureSEC source: 0001144204-18-061226 · tv507710_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335,467 Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:21 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 64,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-052744 · tv504212_form4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331,467 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2018 in the amount of $64,002.62. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 16:05 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 49,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-037836 · tv498254_form4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267,075 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second quarter of 2018 in the amount of $8,880.49, and for the third quarter of 2018 in the amount of $63,844.19. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:06 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 706,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-033542 · tv496161_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,133 F1 · shares: Of the amount shown, 56,880 shares were awarded in lieu of a cash bonus compensation for the fiscal year of 2017 in the amount of $98,345.06. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:13 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 25,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-022388 · tv491870_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,839 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the second quarter of 2018 in the amount of $39,344.17. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 16:17 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 25,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001309 · tv482699_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,303 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the first quarter of 2018 in the amount of $39,922.93. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 16:08 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 21,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-054100 · tv477613_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,864 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the fourth quarter of 2017 in the amount of $39,221.54. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 16:10 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 17,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-036442 · v470582_4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,736 F1 · shares: The reporting person was awarded such securities in exchange for waiving compensation owed for the third quarter of 2017 in the amount of $39,388.96. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 16:16 UTC | DarioHealth Corp. DRIO · Entity 7024 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-021534 · v464822_form4.xml · nonDerivative · entry 1 Raphael Erez · CIK 0001668046 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,700 F1 · shares: The reporting person was awarded such securities as a bonus for the 2016 fiscal year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.